The Engineering Antibodies program continues its quest to present the latest antibodies to watch. The conference will discuss novel platforms to engineer new molecules and emerging formats, such as conditionally-activated antibodies with masking strategies, single domain antibodies for in vivo targeting of intracellular proteins, bi- and multi-specific antibodies for treatment of SARS-CoV-2 as well as novel antibodies against challenging targets.Join us to hear from established biopharm veterans and rishing biotech stars as they share their latest programs and progress updates.